PRINCETON, NJ--(Marketwire -06\/19\/12)- Agile Therapeutics, a pharmaceutical company focused on developing and commercializing more convenient women's contraceptive products, announced today that Al Altomari, President and Chief Executive Officer, will be presenting at the Biotechnology Industry Organization (BIO) International Convention's Business Forum. The event will be taking place June 18-21, 2012 in Boston. <\/p>\n
Mr. Altomari will be speaking at the Business Forum at 9:45 am ET on June 20. His presentation will provide a company update on Agile and a commercialization overview as Agile prepares for its first commercial launch and enters the contraceptive market with AG200-15, a once-weekly, low-dose contraceptive patch. Agile recently filed the NDA for AG200-15, and anticipates a response in 1Q 2013. <\/p>\n
\"I am excited about this opportunity to discuss our strategies for commercialization and growth at this key industry event,\" said Mr. Altomari. \"In support of the anticipated approval and launch of our lead product, AG200-15, we are planning to use the most effective strategies to successfully enter the competitive contraceptive market and respond to a need for more convenient contraceptive choices.\" <\/p>\n
About AG200-15AG200-15 is a combination hormonal contraceptive patch, which in clinical studies has been shown to deliver a low dose of ethinyl estradiol, as well as a dose of levonorgestrel that is consistent with the efficacy and safety profile of low-dose oral contraceptives. The phase III trials for AG200-15 enrolled more than 2,000 women and formed the basis for the Company's application to the US Food and Drug Administration in 2012. <\/p>\n
The AG200-15 patch is applied once weekly for three weeks, followed by a fourth, patch-free week. The patch may be applied to the abdomen, buttocks, or upper torso, is soft and flexible with a cloth-like, silky feel, and designed to provide excellent adhesion, comfort, and appearance. <\/p>\n
About Agile Therapeutics Agile Therapeutics is a pharmaceutical development company specializing in Women's Healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company's lead product, AG200-15, is a once-weekly contraceptive patch that has been submitted to the FDA for approval. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890 (formerly AG900). Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion, developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit http:\/\/www.agiletherapeutics.com<\/a>. <\/p>\n About Biotechnology Industry Organization <\/p>\n BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. For more information, visit http:\/\/www.bio.org<\/a>. <\/p>\n About the BIO International Convention <\/p>\n The annual BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. <\/p>\n<\/p>\n Continued here: PRINCETON, NJ--(Marketwire -06\/19\/12)- Agile Therapeutics, a pharmaceutical company focused on developing and commercializing more convenient women's contraceptive products, announced today that Al Altomari, President and Chief Executive Officer, will be presenting at the Biotechnology Industry Organization (BIO) International Convention's Business Forum. The event will be taking place June 18-21, 2012 in Boston Continue reading
\nAgile Therapeutics to Present at Biotechnology Industry Organization International Convention<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"